cyclin F Inhibitors

Chemical inhibitors of cyclin F primarily function by targeting the cell cycle regulation and DNA repair pathways in which cyclin F is involved. These inhibitors do not directly target cyclin F; instead, they modulate cellular processes and enzymes that are crucial for the function of cyclin F, thereby indirectly affecting its activity. The majority of the identified inhibitors are CDK inhibitors, including Palbociclib, Roscovitine, Flavopiridol, Purvalanol A, Dinaciclib, PD0332991, LY2835219, Ribociclib, Milciclib, Abemaciclib, and AT7519. Cyclin F works in conjunction with cyclin-dependent kinases (CDKs) in regulating the cell cycle and DNA repair processes. By inhibiting CDKs, these compounds disrupt the normal function of the cell cycle regulation machinery. For example, inhibitors like Palbociclib, Ribociclib, and Abemaciclib selectively target CDK4/6, key players in cell cycle progression, particularly in the G1 to S phase transition. By inhibiting these kinases, these compounds can lead to altered cell cycle dynamics, indirectly inhibiting the function of cyclin F in regulating cell cycle progression.

Additionally, compounds like Olomoucine and Roscovitine target a broader range of CDKs. This broad-spectrum inhibition of CDK activities can lead to more widespread disruption in cell cycle regulation, affecting multiple phases where cyclin F is active. By interfering with the activities of various CDKs, these inhibitors can alter the normal progression and checkpoints of the cell cycle, indirectly affecting the regulatory role of cyclin F. These chemical inhibitors of cyclin F demonstrate the interconnected nature of cell cycle regulation and for indirect modulation of specific regulatory proteins like cyclin F. By targeting key enzymes like CDKs, which are crucial for the proper functioning of the cell cycle, these inhibitors can impact the role of cyclin F in cell cycle regulation and DNA repair processes.